NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Shenzhen Majory Biotechnology Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
Palleos Healthcare GmbH
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.